All listings for this product
Best-selling in Non-Fiction Books
Save on Non-Fiction Books
- AU $46.25Trending at AU $49.65
- AU $3.73Trending at AU $7.41
- AU $27.04Trending at AU $31.41
- AU $70.90Trending at AU $78.37
- AU $19.24Trending at AU $24.20
- AU $22.60Trending at AU $23.15
- AU $36.89Trending at AU $46.18
About this product
- DescriptionThe principal purpose of this book is to tell the story of a medicine's journey through the regulatory system in the UK, from defining what counts as a medicine, through clinical trials, licensing, pharmacovigilance, marketing and funding. The question of global access to medicines is addressed because of its political importance, and because it offers a particularly stark illustration of the consequences of classifying medicines as a private rather than a public good. Two further specific challenges to the future of medicine's regulation are examined separately: first, pharmacogenetics, or the genetic targeting of medicines to subgroups of patients, and second, the possibility of using medicines to enhance well-being or performance, rather than treat disease. Throughout, the emphasis is on the role of regulation in shaping and influencing the operation of the medicines industry, an issue that is of central importance to the promotion of public health and the fair and equitable distribution of healthcare resources.
- Author BiographyEmily Jackson is Professor of Law at the London School of Economics.
- Author(s)Emily Jackson
- PublisherBloomsbury Publishing PLC
- Date of Publication01/03/2012
- SubjectLaw: General & Reference
- Place of PublicationOxford
- Country of PublicationUnited Kingdom
- First Published2012
- ImprintHart Publishing
- Content Noteblack & white illustrations
- Weight513 g
- Width156 mm
- Height234 mm
- Spine20 mm
This item doesn't belong on this page.
Thanks, we'll look into this.